ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era

Background and Aim The severity of liver dysfunction in hepatocellular carcinoma (HCC) is often estimated with Child–Turcotte–Pugh (CTP) classification or model for end‐stage liver disease (MELD) score. We aim to investigate the performance of albumin‐bilirubin (ALBI) and platelet‐albumin‐bilirubin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gastroenterology and hepatology 2017-04, Vol.32 (4), p.879-886
Hauptverfasser: Liu, Po‐Hong, Hsu, Chia‐Yang, Hsia, Cheng‐Yuan, Lee, Yun‐Hsuan, Chiou, Yi‐You, Huang, Yi‐Hsiang, Lee, Fa‐Yauh, Lin, Han‐Chieh, Hou, Ming‐Chih, Huo, Teh‐Ia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and Aim The severity of liver dysfunction in hepatocellular carcinoma (HCC) is often estimated with Child–Turcotte–Pugh (CTP) classification or model for end‐stage liver disease (MELD) score. We aim to investigate the performance of albumin‐bilirubin (ALBI) and platelet‐albumin‐bilirubin (PALBI) grade, which are recently reported to be simple and objective measurements for liver reserve in HCC. Methods Between 2002 and 2014, consecutive 3182 HCC patients were enrolled to follow up their survival. The area under receiver‐operator‐characteristic curve (AUC) was calculated to test the discriminatory powers over 1‐year, 3‐year, and 5‐year survival. Results Significant survival differences were found across all ALBI and PALBI grades (both P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.13608